MA38390B1 - Composés tétrahydropyrrolothiazines - Google Patents

Composés tétrahydropyrrolothiazines

Info

Publication number
MA38390B1
MA38390B1 MA38390A MA38390A MA38390B1 MA 38390 B1 MA38390 B1 MA 38390B1 MA 38390 A MA38390 A MA 38390A MA 38390 A MA38390 A MA 38390A MA 38390 B1 MA38390 B1 MA 38390B1
Authority
MA
Morocco
Prior art keywords
tetrahydropyrrolothiazine
compounds
tetrahydropyrrolothiazine compounds
compound
formula
Prior art date
Application number
MA38390A
Other languages
English (en)
Other versions
MA38390A1 (fr
Inventor
Steven James Green
Dustin James Mergott
Brian Morgan Watson
Jr Leonard Larry Winneroski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA38390A1 publication Critical patent/MA38390A1/fr
Publication of MA38390B1 publication Critical patent/MA38390B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne un composé de formule (i), dans laquelle r est h ou f ; et a est : (a), (b), (c) ou (d) ; ou un sel pharmaceutiquement acceptable de celui-ci.
MA38390A 2013-03-12 2014-03-04 Composés tétrahydropyrrolothiazines MA38390B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776819P 2013-03-12 2013-03-12
PCT/US2014/020070 WO2014143579A1 (fr) 2013-03-12 2014-03-04 Composés tétrahydropyrrolothiazines

Publications (2)

Publication Number Publication Date
MA38390A1 MA38390A1 (fr) 2018-08-31
MA38390B1 true MA38390B1 (fr) 2020-01-31

Family

ID=50382615

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38390A MA38390B1 (fr) 2013-03-12 2014-03-04 Composés tétrahydropyrrolothiazines

Country Status (38)

Country Link
US (3) US8841293B1 (fr)
EP (1) EP2970336B1 (fr)
JP (1) JP6095844B2 (fr)
KR (1) KR101688761B1 (fr)
CN (1) CN105026404B (fr)
AP (1) AP2015008713A0 (fr)
AR (1) AR094918A1 (fr)
BR (1) BR112015018738A8 (fr)
CA (1) CA2898500C (fr)
CL (1) CL2015002529A1 (fr)
CR (1) CR20150418A (fr)
CY (1) CY1119585T1 (fr)
DK (1) DK2970336T3 (fr)
EA (1) EA026006B1 (fr)
ES (1) ES2653421T3 (fr)
HK (1) HK1212694A1 (fr)
HR (1) HRP20171851T1 (fr)
HU (1) HUE037487T2 (fr)
IL (1) IL240903B (fr)
JO (1) JO3317B1 (fr)
LT (1) LT2970336T (fr)
MA (1) MA38390B1 (fr)
ME (1) ME02910B (fr)
MX (1) MX2015012628A (fr)
MY (1) MY180083A (fr)
NO (1) NO3039297T3 (fr)
NZ (1) NZ712207A (fr)
PE (1) PE20151542A1 (fr)
PH (1) PH12015502031B1 (fr)
PL (1) PL2970336T3 (fr)
PT (1) PT2970336T (fr)
RS (1) RS56645B1 (fr)
SG (1) SG11201507499XA (fr)
SI (1) SI2970336T1 (fr)
TN (1) TN2015000340A1 (fr)
TW (1) TWI593692B (fr)
UA (1) UA112941C2 (fr)
WO (1) WO2014143579A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201492223A1 (ru) 2012-06-13 2015-03-31 Ф. Хоффманн-Ля Рош Аг Новые диазаспироциклоалканы и азаспироциклоалканы
EP2900669B1 (fr) 2012-09-25 2019-09-04 F.Hoffmann-La Roche Ag Dérivés du héxahydropyrrolo[3,4-c]pyrrole et composés similaires en tant qu'inhibiteurs de l'autotaxine (atx) et inhibiteurs de la production de l'acid lysophosphatidique (lpa) pour traiter des maladies rénales
SI2912041T1 (sl) 2012-10-26 2017-02-28 Eli Lilly And Company Derivati tetrahidropirolotiazina kot inhibitorji beta sekretaze (bace)
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
KR20160087900A (ko) 2013-11-26 2016-07-22 에프. 호프만-라 로슈 아게 신규한 옥타하이드로-사이클로부타[1,2-c；3,4-c'']다이피롤-2-일
TWI684452B (zh) 2014-03-14 2020-02-11 美國禮來大藥廠 胺基噻嗪化合物
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
UA119347C2 (uk) 2014-03-26 2019-06-10 Ф. Хоффманн-Ля Рош Аг Конденсовані [1,4]діазепінові сполуки як інгібітори продукції аутотаксину (atх) та лізофосфатидилової кислоти (lpa)
TWI570127B (zh) * 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
TWI574969B (zh) * 2015-01-30 2017-03-21 美國禮來大藥廠 甲苯磺酸鹽
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AR104241A1 (es) 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
AU2016316717B2 (en) 2015-09-04 2021-02-18 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
MX2018001430A (es) 2015-09-24 2018-04-20 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
KR20180053408A (ko) 2015-09-24 2018-05-21 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서의 신규한 이환형 화합물
WO2017050792A1 (fr) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
EP3353180B1 (fr) 2015-09-24 2022-03-16 F. Hoffmann-La Roche AG Composes bicycliques utiles comme inhibiteurs atx
AR107774A1 (es) 2016-03-16 2018-05-30 Lilly Co Eli Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
JP7148518B2 (ja) 2016-12-15 2022-10-05 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としての二環式チアジンおよびオキサジン誘導体ならびに使用方法
WO2018112086A1 (fr) 2016-12-15 2018-06-21 Amgen Inc. Derivés thiazine fusionnés à un cyclopropyle utilisés en tant qu'inhibiteurs de la bêta-sécrétase et procédés d'utilisation
US10947223B2 (en) 2016-12-15 2021-03-16 Amgen Inc. Substituted oxazines as beta-secretase inhibitors
MA50007A (fr) 2016-12-15 2021-04-07 Amgen Inc Dérivés de dioxyde de 1,4-thiazine et de dioxyde de 1,2,4-thiadiazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
WO2018112083A1 (fr) 2016-12-15 2018-06-21 Amgen Inc. Dérivés de thiazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2003082856A1 (fr) * 2002-03-22 2003-10-09 Eli Lilly And Company Derives d'acide isoquinoline-3-carboxylique en tant qu'antagonistes du recepteur d'acide amine excitateur
KR20080029965A (ko) * 2005-06-14 2008-04-03 쉐링 코포레이션 아스파르틸 프로테아제 억제제
ES2572263T3 (es) 2005-10-25 2016-05-31 Shionogi & Co Derivados de dihidrooxazina y tetrahidropirimidina como inhibidores de BACE 1
EP2151435A4 (fr) 2007-04-24 2011-09-14 Shionogi & Co Composition pharmaceutique pour le traitement de la maladie d'alzheimer
ES2548774T3 (es) 2008-01-18 2015-10-20 Eisai R&D Management Co., Ltd. Derivado de aminodihidrotiazina condensado
EP2283016B1 (fr) * 2008-04-22 2014-09-24 Merck Sharp & Dohme Corp. Composes de 2-imino-3-methyl-pyrrolo pyrimidinone substitues par thiophenyle utilises en tant qu inhibiteurs bace-1, compositions et utilisation associees
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
CA2738150A1 (fr) 2008-09-30 2010-04-08 Eisai R&D Management Co., Ltd. Derive d'aminodihydrothiazine fusionne inedit
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
JPWO2011071109A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 アミノ基を有する縮合ヘテロ環化合物
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
EP2694521B1 (fr) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Composés de dioxyde de thiadiazine fusionnée à la pyrrolidine en tant qu'inhibiteurs de bace, compositions et leur utilisation
AR086539A1 (es) 2011-05-24 2014-01-08 Bristol Myers Squibb Co COMPUESTOS PARA LA REDUCCION DE LA PRODUCCION DE b-AMILOIDE
JO3143B1 (ar) * 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين

Also Published As

Publication number Publication date
AP2015008713A0 (en) 2015-09-30
IL240903A0 (en) 2015-10-29
KR101688761B1 (ko) 2016-12-21
US8987254B2 (en) 2015-03-24
PE20151542A1 (es) 2015-10-28
US20140275044A1 (en) 2014-09-18
TN2015000340A1 (en) 2017-01-03
CR20150418A (es) 2015-09-16
HK1212694A1 (zh) 2016-06-17
JP6095844B2 (ja) 2017-03-15
TWI593692B (zh) 2017-08-01
CY1119585T1 (el) 2018-03-07
MX2015012628A (es) 2016-07-07
AU2014228351A1 (en) 2015-09-17
IL240903B (en) 2018-12-31
CA2898500C (fr) 2017-11-14
PL2970336T3 (pl) 2018-03-30
CN105026404A (zh) 2015-11-04
BR112015018738A2 (pt) 2017-07-18
MA38390A1 (fr) 2018-08-31
EP2970336B1 (fr) 2017-10-04
PT2970336T (pt) 2017-12-21
NZ712207A (en) 2019-09-27
NO3039297T3 (fr) 2018-03-10
ES2653421T3 (es) 2018-02-07
ME02910B (fr) 2018-04-20
US8841293B1 (en) 2014-09-23
HUE037487T2 (hu) 2018-08-28
US20150157641A1 (en) 2015-06-11
CA2898500A1 (fr) 2014-09-18
CN105026404B (zh) 2016-11-23
MY180083A (en) 2020-11-20
JP2016512252A (ja) 2016-04-25
WO2014143579A1 (fr) 2014-09-18
EA201591491A1 (ru) 2016-01-29
EA026006B1 (ru) 2017-02-28
CL2015002529A1 (es) 2016-03-28
PH12015502031A1 (en) 2016-01-18
LT2970336T (lt) 2018-01-10
AR094918A1 (es) 2015-09-09
UA112941C2 (uk) 2016-11-10
PH12015502031B1 (en) 2016-01-18
US20140350245A1 (en) 2014-11-27
SG11201507499XA (en) 2015-10-29
TW201520217A (zh) 2015-06-01
SI2970336T1 (sl) 2017-11-30
KR20150119070A (ko) 2015-10-23
EP2970336A1 (fr) 2016-01-20
HRP20171851T1 (hr) 2018-01-12
RS56645B1 (sr) 2018-03-30
BR112015018738A8 (pt) 2018-01-23
DK2970336T3 (da) 2017-11-13
JO3317B1 (ar) 2019-03-13

Similar Documents

Publication Publication Date Title
MA38390B1 (fr) Composés tétrahydropyrrolothiazines
MA52948B1 (fr) Composés
MA38472B1 (fr) Composé peptidique
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
BR112017006253A2 (pt) novos compostos
MA46337A (fr) Composé de pyridine
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
EA201690172A1 (ru) Полиморф ингибиторов syk
MA40302B1 (fr) Dérivés de carbazole
EA201792021A1 (ru) Ингибитор jak
EA201690911A1 (ru) Соединения диметилбензойной кислоты
MA38583B1 (fr) Dérivés de dolastatine 10 et d'auristatines
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
MA37686B1 (fr) Composés phénoxyéthyl pipéridine
MA37501B1 (fr) Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
MA39305A3 (fr) Dérivés d'éthynyle
EA201690924A1 (ru) Фторфенилпиразольные соединения
MA44781B1 (fr) Composé hétérocyclique condensé
MA38857A1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
MA43231B1 (fr) Bloqueur des canaux sodiques
MA38991B1 (fr) Dérivés d'indole-urée substitués par un glucopyranosyle et leur utilisation à titre d'inhibiteurs de sglt